| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 08/18/2005 | WO2005074884A2 Sustained release pharmaceutical composition of indapamide |
| 08/18/2005 | WO2005074883A1 Aqueous compositions containing mixtures of synthetic polymers and biopolymers, useful in the treatment of skin and mucosal tissues dryness, and suitable as vehicles of active ingredients |
| 08/18/2005 | WO2005074882A2 Flat system for using in the oral cavity |
| 08/18/2005 | WO2005074836A1 Methods for progenitor cell recruitment and isolation |
| 08/18/2005 | WO2005074835A1 Hydrophilic matrix for delivery of active agent and product containing same |
| 08/18/2005 | WO2005074718A1 Pharmaceutical or dietary compositions based on short-chain fatty acids and complex sugars, for intestinal disorders |
| 08/18/2005 | WO2005074699A2 Method for the production of solid dispersions |
| 08/18/2005 | WO2005074378A2 Device and method for reducing calorie intake |
| 08/18/2005 | WO2005074353A2 Sterile in-situ microcarrier forming gelled polymeric dispersions and processes to manufacture the same |
| 08/18/2005 | WO2005058385A3 Multiple section parenteral drug delivery apparatus |
| 08/18/2005 | WO2005056037B1 Metered dose inhalation preparations of proteins and peptides |
| 08/18/2005 | WO2005055921A3 Compositions for treatment of ear disorders and methods of use thereof |
| 08/18/2005 | WO2005053608A3 Preparing for individualized dosage forms of medicaments |
| 08/18/2005 | WO2005051350A3 Water dispersible tablet |
| 08/18/2005 | WO2005044240A3 Stable lansoprazole formulation |
| 08/18/2005 | WO2005044234A3 Nanoparticulate compositions having a peptide as a surface stabilizer |
| 08/18/2005 | WO2005044230A3 Controlled release analgesic suspensions |
| 08/18/2005 | WO2005032513A3 Pantoprazole multiparticulate formulations |
| 08/18/2005 | WO2005021065A3 Indirect delivery of growth factors into the central nervous system |
| 08/18/2005 | WO2005000268A3 Bioerodible sustained release drug delivery systems |
| 08/18/2005 | WO2004112750A3 Ophthalmic compositions containing a synergistic combination of three polymers |
| 08/18/2005 | WO2004110411A3 Orally-dispersible multilayer tablet |
| 08/18/2005 | WO2004100931A3 Use of soaps such as magnesium stearate for increasing the release of drugs |
| 08/18/2005 | WO2004091527A3 Delivery systems of homogeneous thermoreversible low viscosity polymannan gum films |
| 08/18/2005 | WO2004027822A3 Oriented nanostructures and methods of preparing |
| 08/18/2005 | US20050182496 Soft tissue implants and anti-scarring agents |
| 08/18/2005 | US20050182469 Electrical devices and anti-scarring agents |
| 08/18/2005 | US20050182468 Electrical devices and anti-scarring agents |
| 08/18/2005 | US20050182467 Electrical devices and anti-scarring agents |
| 08/18/2005 | US20050182463 Polymer compositions and methods for their use |
| 08/18/2005 | US20050182450 Electrical devices and anti-scarring agents |
| 08/18/2005 | US20050182391 Administering device with an osmotic drive |
| 08/18/2005 | US20050182390 Implantable drug delivery device including wire filaments |
| 08/18/2005 | US20050182236 Star polymer such as of a polylactone based on a central phosphorus atom derived from phosphorus oxychloride (POCl3) or ethyl dichlorophosphate; biodegradable and/or biocompatible; sustained release drug delivery; reverse thermal gelation |
| 08/18/2005 | US20050182056 Modified release formulations of at least one form of tramadol |
| 08/18/2005 | US20050182039 Use of Loteprednol etabonate for the treatment of dry eye |
| 08/18/2005 | US20050182036 Medicinal composition containing an HMG-CoA reductase inhibitor |
| 08/18/2005 | US20050182030 Antitumor, anticancer agents; osteoporosis; bone disorders; Paget's disorders; solution is provided in a sealed non-reactive plastic container of polypropylene, ABS, polyethylene, PVC, polycycloolefin; injectable, sterile, ready to use, pyrogen-free solution |
| 08/18/2005 | US20050182026 Dioleyl phosphatidylcholine (DOPC); distearyl phosphatidylcholine (DSPC) and dipalmitoyl phosphatidylcholine (DPPC) as surface active phosphotidyls; phosphatidyl glycerol, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, or chlorestyl palmitate as spreading agent |
| 08/18/2005 | US20050182017 Immunostimulatory nucleic acid molecules |
| 08/18/2005 | US20050181999 Comprising a biologically active agent (e.g., antifungal) , urea and an acid (lactic acid) or ethoxydiglycol; provide better bioavailability of the active agent within the nail |
| 08/18/2005 | US20050181976 coupled to therapeutic proteins or peptides; biochemical conjugation |
| 08/18/2005 | US20050181516 Bioequivalence determination using expression profiling |
| 08/18/2005 | US20050181163 Sheet-type patch |
| 08/18/2005 | US20050181064 Drugs comprising protein forming hollow nanoparticles and therapeutic substance to be transferred into cells fused therewith |
| 08/18/2005 | US20050181063 Biologically active agent being encapsulated within microspheres which comprise a polymer which has a molecular weight in excess of 94 kDa and a maximum diameter of 20 mu m; for the intra-nasal administration of vaccines in a single shot vaccination |
| 08/18/2005 | US20050181062 Comprises crystalline drug (azithromycin, amlodipine, cetirizine), a glyceride with an alkylate substituent (palmitate, stearate, oleate, linoleate, arachidate) , and a poloxamer |
| 08/18/2005 | US20050181061 Extrusion/melt-congeal process; reduced drug degradation |
| 08/18/2005 | US20050181060 Method of making pharmaceutical multiparticulates |
| 08/18/2005 | US20050181059 Mixing a nonsolvent (tert-butyl alcohol) that is miscible with water with the aqueous solution and precipitating particles of the biologically active agents out of the nonsolvent |
| 08/18/2005 | US20050181058 Use of polysaccharides, such as galactomannans, glucomannans and the like for introducing active substances into the human or animal metabolism |
| 08/18/2005 | US20050181057 Vaginal lubricant |
| 08/18/2005 | US20050181055 Includes a therapeutically effective amount of quinapril or an acid addition salt thereof and between about 15- 40% w/w of an alkaline substance; angiotensin-converting enzyme (ACE) inhibitor; hypertension, heart failure and angioedema |
| 08/18/2005 | US20050181054 comprising a water-insoluble and/or water-low soluble substance, a medicament, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm; efficient penetration and high permeability blood at the mucosa |
| 08/18/2005 | US20050181053 Comprises methacrylic acid-methyl methacrylate copolymer layers for drug delivery to gastrointestinal tract ; solid unit dosage form for oral administration; improved resistance to coating fractures |
| 08/18/2005 | US20050181052 Lansoprazole microtablets |
| 08/18/2005 | US20050181051 Contains Cefixime Trihydrate, Cloxacillin Sodium (sustained release and immediate release form), Lactobacillus sporogenes spores |
| 08/18/2005 | US20050181050 Dosage forms using drug-loaded ion exchange resins |
| 08/18/2005 | US20050181049 Composition and method for enhancing bioavailability |
| 08/18/2005 | US20050181048 Compositions and methods for timed release of a water-soluble nutritional supplement, methylsulfonylmethane |
| 08/18/2005 | US20050181047 Provides a longer delay and a high concentration of a nutritional supplement whose dissolution allows greater flexibility in designing timed release profiles |
| 08/18/2005 | US20050181046 Tamper-resistant oral opioid agonist formulations |
| 08/18/2005 | US20050181045 Vaginally administrable progesterone-containing tablets and method for preparing same |
| 08/18/2005 | US20050181044 Compositions and methods for timed release of water-soluble nutritional supplements, green coffee extract |
| 08/18/2005 | US20050181043 Particle size distribution; drug package comprising a high density polyethylene bottle comprising alendronate sodium; do not require lactose or polyvinylpyrrolidone in order to achieve blend uniformity; administered as inhibitor of osteoclast-mediated bone bioresorption |
| 08/18/2005 | US20050181042 Composition for oral or rectal administration |
| 08/18/2005 | US20050181041 Forming solution of drugs, dietary supplements, and/or agrochemicals and crystal lattice modifier dissolved in a solvent; mixing with nonsolvent; crystallization; drug delivery; stability |
| 08/18/2005 | US20050181040 Progestagenic dosage unit |
| 08/18/2005 | US20050181039 Micelles |
| 08/18/2005 | US20050181038 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 08/18/2005 | US20050181037 Cardiolipin compositions their methods of preparation and use |
| 08/18/2005 | US20050181036 Lipid vehicle which can be nebulized comprising curcumin, lipids, and aqueous solvent; bioavailability; administering antiproliferative, anticarcinogenic, antiasthmatic, antiischemic, antiinflammatory and/or antibiotic agents; respiratory, neurodegenerative, brain, autoimmune, and rheumatic diseases |
| 08/18/2005 | US20050181035 Liposome delivery vehicle; nucleic acid consisiting of an oligonucleotide containing no CpG motifs; and a nucleic acid vector without a gene insert, or fragment thereof; anticarcinogenic, antiallergen, and antiinflammatory agents |
| 08/18/2005 | US20050181034 3-Amidino- or 3-guanidino phenylalanine derivative which is effective as urokinase inhibitor; antitumor, anticarcinogenic, and antimetastasis agents |
| 08/18/2005 | US20050181032 Metastable pharmaceutical compositions |
| 08/18/2005 | US20050181031 Permeation enhancer comprising fatty acid ester and/or a terpene; urogenital and respiratory system disorders |
| 08/18/2005 | US20050181030 Topical stabilized prostaglandin E compound dosage forms |
| 08/18/2005 | US20050181029 Skin patch having a plurality of drug reservoirs arranged in a matrix, serving to divide the area of contact with skin into a plurality of smaller areas; delivery of high molecular weight drugs |
| 08/18/2005 | US20050181026 Lactate and glucose supply; 2-acrylamido-2-methylpropanesulfonic acid, sodium salt (Lubrizol), polyoxyethylene glycol diacrylate, photoinitiator of 1-hydroxycyclohexyl phenyl ketone, glucose, zinc lactate, potassium iodide, and deionized water; wound healing agents |
| 08/18/2005 | US20050181025 Physiologically acceptable salt of hyaluronic acid, iodine and potassium iodine; disinfects wound and reduces infection, removes secretions thereby reducing maceration, maintains wound hydration, and enhances granulation and epithelial cell formation of wounded tissue |
| 08/18/2005 | US20050181023 Drug-enhanced adhesion prevention |
| 08/18/2005 | US20050181021 Liposomes in food, beverage, or nutritional supplement; prophylaxis; encapsulated, sonicated |
| 08/18/2005 | US20050181018 Ocular drug delivery |
| 08/18/2005 | US20050181017 Compositions and methods for localized therapy of the eye |
| 08/18/2005 | US20050181015 Drug loaded nanoparticles dispersed within polymeric carrier, said drug loaded nanoparticles comprising a layered silicate material such as smectite clay and a first therapeutic agent; allows hydrophobic therapeutic agents to be incorporated into hydrophilic carrier regions, and vice versa |
| 08/18/2005 | US20050181010 Breast, pectoral, chin, facial, lip, and nasal implants; inhibits angiogenesis and fibroblast migration; enzyme inhibitors; glucose monitor |
| 08/18/2005 | US20050181009 Breast, pectoral, chin, facial, lip, and nasal implants; inhibits angiogenesis and fibroblast migration; enzyme inhibitors |
| 08/18/2005 | US20050181007 To inhibit scarring when the implant is placed within an animal; breast impant for reconstruction or cosmetic implants; antiscarring agent can be a taxane |
| 08/18/2005 | US20050181005 Breast, pectoral, chin, facial, lip, and nasal implants; inhibits angiogenesis and fibroblast migration; enzyme inhibitors |
| 08/18/2005 | US20050181000 Polymeric nanoparticles in consumer products |
| 08/18/2005 | US20050180992 Fabricating wet spun or electrospun fibers using nanometer scale liquid crystalline viral particle suspensions where particle composition and function can be modified genetically to include binding or nucleating conjugate moieties while maintaining fibrous structure end product |
| 08/18/2005 | US20050180974 directly delivering interleukin 10 signal transduction modifying agent to cerebrospinal fluid and/or brain tissue |
| 08/18/2005 | US20050180965 Heat-reversible composition treating hyposalia and asialia |
| 08/18/2005 | US20050180962 treating a non-alcoholic fatty liver disease; inactivated probiotic bacteria; and a pharmaceutically acceptable excipient; gastrointestinal inflammation; allergic asthma |
| 08/18/2005 | US20050180960 producer cell (encapsulated in a matrix containing immunostimulating alginates) expresses a molecule that is an inhibitor of the growth of a CNS tumor |
| 08/18/2005 | US20050180926 Inhalable aerosol medicament for the treatment or prevention of pain |
| 08/18/2005 | US20050180925 Formulations and methods for treating rhinosinusitis |
| 08/18/2005 | US20050180924 Composition and method for moisturizing nasal tissue |
| 08/18/2005 | US20050180923 Buccal, polar and non-polar spray containing testosterone |
| 08/18/2005 | US20050180922 able to incorporate a range of hydrophobic drugs into the cores; preferred copolymers comprise a hydrophilic PEO (polyethylene oxide) block and one of several hydrophobic blocks that drive self-assembly |